Fragile X Syndrome (FXS) is a rare genetic disorder leading to developmental issues such as learning disabilities and cognitive impairment, predominantly affecting males more severely. It is a leading cause of inherited intellectual disability and autism, stemming from the silencing of the Fmr1 gene, which impairs BK channel function crucial for neuron communication.
Spinogenix has recently received FDA approval for a Phase II clinical trial of SPG601, a novel small molecule BK channel activator designed to restore synaptic function by increasing BK channel activation. This trial will evaluate the neurophysiological and clinical impacts of SPG601, administered as a once-a-day pill, in adult men with FXS, comparing its effectiveness in altering disease markers and alleviating symptoms against a placebo.
Concurrently, the European Commission has granted orphan medicinal product designation to Shionogi’s zatolmilast (BPN14770), a cAMP-specific 3′,5′ cyclic phosphodiesterase 4D inhibitor, for FXS treatment. Zatolmilast, developed by Tetra Therapeutics under Shionogi, has shown significant cognitive benefits in a Phase II trial, particularly in oral reading recognition, picture vocabulary, and cognition crystallised composite score among males aged 18 to 45 years.
These developments represent significant strides towards addressing the lack of approved treatments for FXS, which currently relies on off-label drugs targeting individual symptoms. The advancements by Spinogenix and Shionogi offer hope for more effective and patient-friendly solutions for those affected by FXS.
